Shandong Weigao reported QQ2 2025 revenue of 3.322 billion CNY, up 105.97% year over year and 100% quarter over quarter, signaling a powerful rebound from prior-period baselines. The quarter delivered a gross margin of 49.72% (gross profit of 1.6517 billion CNY) with an EBITDA of 819.20 million CNY and an operating income of 587.87 million CNY, translating to an operating margin of 17.70% and a net margin of 15.18% (net income of 504.16 million CNY). Diluted earnings per share stood at 0.11 CNY. The company’s balance sheet remains liquidity-rich, with a current ratio of 3.73 and a debt ratio of 0.153, underscoring conservative leverage alongside robust cash generation. Cash per share is 2.11 CNY, and the payout ratio is 55.7%, indicating a healthy approach to shareholder returns while maintaining balance sheet flexibility. The trailing four-quarter revenue runs at approximately 6.64 billion CNY, illustrating a meaningful growth trajectory when viewed on a twelve-month basis. While management commentary is not provided in the dataset, the results imply continued strength in domestic hospital demand, disciplined cost management, and potential operating leverage as the company expands its single-use medical device portfolio. Investors should monitor hospital capex cycles, material costs, and competitive dynamics within the Chinese medical device space, where margin dispersion exists across peers.